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 As drug development becomes a long and demanding process, it might also 
become a barrier to medical progress. Drug safety concerns are responsible for many of 
the resources consumed in launching a new drug. Despite the money and time expended 
on it, a significant number of drugs are withdrawn years or decades after being in the 
market. Cardiovascular toxicity is one of the major reasons for those late withdrawals, 
meaning that many patients are exposed to unexpected serious cardiovascular risks. It 
seems that current methods to assess cardiovascular safety are imperfect, so new 
approaches to avoid the exposure to those undesirable effects are quite necessary. 
Endothelial dysfunction is the earliest detectable pathophysiological abnormality, which 
leads to the development of atherosclerosis, and it is also an independent predictor for 
major cardiovascular events. Endothelial toxicity might be the culprit of the 
cardiovascular adverse effects observed with a significant number of drugs. In this article 
we suggest the regular inclusion of the best-validated and less invasive endothelial 
function tests in the clinical phases of drug development, in order to facilitate the 








THE CURRENT PROBLEM OF DRUG DEVELOPMENT  
The process of drug development is complex, time-consuming and costly. After a 
preclinical phase -which could take more than 4 years- the approval of an investigational 
new drug application to the Food and Drug Administration (FDA) is required, and only 
then the clinical phases I, II, and III are ready to be started. Following their completion, 
FDA can approve or reject the new drug, or can also request for more studies before a 
decision. The entire process can rarely be completed in less than 12 years [1]. Moreover, 
for every 5000 compounds that initiated the preclinical phase only one will reach the 
market [2], and the current cost of developing a new drug is continuously growing, 
nowadays it is estimated to exceed US $990 million [3].  
A negative consequence of this challenging path has been the significant decline 
in the number of new drugs submitted to the FDA, not in parallel with the increased 
number of relevant biomedical discoveries. This wide gap between basic research and 
clinical application could impede innovation and limit the number of therapies available 
for several diseases [4]. A concern about this problem has arisen, and some strategies to 
improve this critical path from laboratory concept to commercial product are being 
developed. In the case of medical products performance is evaluated as safety and 
effectiveness, so one of these requests is for creating new tools to demonstrate them in a 
more accurate, faster and lower-cost approach [4-6]. 
 
Toxicity in drug development 
In the past, adverse pharmacokinetic and bioavailability were responsible for the 
majority of attrition in drug development; currently these reasons contribute less than 
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10%, and the primary causes are the lack of efficacy (30%) and toxicity (30%). These 
problems are considerable contributors to the elevated cost of the process, as tend to be 
recognized in latter stages (phases II and III) or even after marketing [7]. In addition, it is 
known that over 90% of the market withdrawals are due to drug toxicity, which can lead 
to a huge expenditure of money and time [8]. For example, it was estimated that the 
financial and legal cost of withdrawing rofecoxib cost Merck around US $28 billion [9].   
Although safety issues are a cause of delay and discontinuation during the 
process, and even a possibility of eliminating unnecessarily potential candidates exists, it 
seems neither practical nor ethical to simply lower the safety standards, as some people 
have proposed. We expect marketed drugs to have a well-understood safety profile and a 
positive benefit/risk balance. However, despite the major relevance of safety 
assessment, there have been little changes over the years in the traditional tools used for it 
[4-6]. But even more, some concerns are present regarding a higher likelihood, compared 
to previous decades, of unanticipated safety problems once the drug is approved [10], and 
about an inexplicable deferral in removing those drugs from the market following the 
detection of severe side effects [11, 12].  
The determinants for these safety deficits are diverse and not unique. Among the 
reason we could include: the lack of specificity to predict the adverse effects in humans 
that classical animal toxicology may have; the narrow spectrum of patients profiles 
enrolled in clinical phases that can differ importantly from the population that will 
receive the treatment after the approval; the incapacity to detect during the short follow-
up of clinical trials those side effects which appear in a very late stage; and the fact that 
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serious adverse drug reactions (ADRs) are often so rare that a huge number of individuals 
are required to identify them [4, 5, 8]. 
 
CARDIOVASCULAR SAFETY 
The high number of treatments developed for cardiovascular diseases may also 
have undesirable negative effects on the same anatomy where they act. Besides, the 
cardiovascular system has proven to be particularly sensitive to a large variety of 
interaction with drugs prescribed for a different therapeutic indication. In result, the 
cardiovascular system is the most frequent sites of ADRs, and cardiovascular safety is the 
major cause for drug discontinuation at all stages of drug development in United States 
[13]. 
Unfortunately, its leadership does not seem to have changed during last decades. 
Some years ago, Lasser et al. [14] analyzed the period from 1975 to 2000 and found 81 
major changes to drug labeling in the Physicians’ Desk Reference, including the addition 
of one or more black box warnings or drug withdrawal. Cardiovascular (21%) and 
hepatic (19%) toxicities were the main culprits of those changes. Afterwards, Schuster et 
al. [8] studied the reasons for drug withdrawals from European and American markets 
between 1992 and 2002. They collected a total of 16 drugs withdrawals, 94% of them due 
to safety problems. Again cardiovascular (40%) and hepatic (27%) toxicities were the 
principal contributors for market discontinuation. And more recently, concordant data 
coming from two pharmaceutical companies (DuPont-Merck and Bristol-Myers-Squibb) 
during 1993-2006 [15], describe how the most frequent organs or tissues affected by 
toxicity are the cardiovascular system (27.3%) and the liver (14.8%). 
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Mechanisms and evaluation of cardiovascular toxicity 
 A chemical compound may impair the cardiovascular system performance 
through three particular mechanisms: inducing direct myocardial injury, promoting 
proarrhythmic changes and/or altering the vascular integrity and tone. The consequences 
of these insults depend on both the drug (type, dose, time of exposure) and the patient 
(age, gender, race, healthy status, concomitant treatments). Based on that, their 
magnitude may be quite diverse: from cardiovascular death or severe irreversible injuries 
(e.g. myocardial or cerebral infarction), to symptomatic or asymptomatic reversible 
effects (e.g. deterioration of ventricular ejection fraction, non-lethal arrhythmias), or 
pathophysiological alterations that could predispose the patient to future cardiovascular 
events (e.g. hypertension, arrhythmogenic or thrombogenic substrates) [16, 17].  
 The current approaches for assessing cardiovascular safety of new drugs, and their 
particular limitations, have been recently and extensively reviewed in the literature. As a 
brief summary, the direct drug-induced myocardial injury can be evaluated from the 
examination of isolated cultured cardiomyocytes or histopathological tissue samples from 
animals, and with the use of different biomarkers (troponins, natriuretic peptides), 
imagine (echocardiography, magnetic resonance imaging) and invasive techniques 
(hemodynamic catheterization) [13, 16-18]. The proarrhythmic risk, which has received 
great attention in last years [19, 20], has been traditionally estimated with the functional 
evaluation of the potassium channel (IKr) responsible of most drug-related long QT 
syndromes (hERG assay), the study of action potentials in isolated cardiac tissues, and 
with continuous monitorization of arrhythmias and electrocardiographic intervals 
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(electrocardiograms, telemetry); however more recently a new cardiac proarrhythmia 
safety paradigm has been proposed, it is labeled the “Comprehensive In vitro 
Proarrhythmia Assay” (CiPA) and includes in silico predictive modelling of cellular 
electrophysiological effects [21]. 
But, as previously recognized [13, 17, 22], little efforts (e.g. lipid profile, 
inflammatory markers, blood pressure monitoring) have been done to analyze the drug-
related pathophysiological alterations that could produce middle-long term effects in the 
cardiovascular system. Most of the interest has been exclusively focused on the acute and 
proarrhythmic consequences of the new compounds, especially their risk of QT 
prolongation. 
 
The present of cardiovascular toxicity 
We have performed a search for the marketed drugs withdrawn by FDA during a 
5 year period (2005 - 2010) [23]. At our knowledge, there have been at least 5 
withdrawals related to an associated increased cardiovascular risk (Table 1). In addition, 
12 safety alerts concerning increased cardiovascular risk associated with the use of 
various compounds have been published in the same period (Table 2).  
In agreement with the data reported by Lasser et al [14], in both tables we can 
visualize how the majority of ADRs are discovered years, even decades, after the drugs 
are on market. Likewise, it should also be noted that QT prolongation is still one of the 
most frequent reason for cardiovascular safety alert, but clearly, it is not the only 
responsible.  
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  Remarkably, as a good demonstration of the uncertain current times, even 
acetaminophen -which is traditionally considered the drug of choice for pain relief in 
patients with cardiovascular disease due to its theoretical cardiovascular safety-, has 
recently shown to significantly increase heart rate and blood pressure compared to 
placebo [24], in similarity with many nonsteroidal antiinflammatory drugs (NSAIDs) 
[25].  
The relevance of the cardiovascular safety assessment in the process of drug 
development is never sufficiently highlighted. With the present delays in detecting this 
toxicity, we are exponentially increasing the cost, being at risk of ending the research in 
new molecules, and so taking away the hope for thousand of patients. For instance, it has 
been suggested [26] that one of the Pfizer’s reasons to interrupt development of new 
drugs in cardiovascular area were the results (increased deaths and cardiovascular events) 
in a phase III clinical trial with torcetrapib [27]. 
At this point, it is reasonable to conclude that cardiovascular toxicity continues to 
be underestimated at drug’s market launch, and that current methods to select drugs with 
a proper cardiovascular safety profile are still inaccurate and insufficient. So, we have an 
imperative need for new approaches to help us to deliver cardiovascular safe drugs at 
acceptable times and reasonable cost, avoiding patients to exposure unnecessarily to 
deleterious cardiovascular ADRs.  
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Table 1. Drugs withdrawn from the market based on cardiovascular safety concerns between 2005 
and 2010 
 
Drug Name Brand Name Company 
Approval 





Propoxyphene Darvon Xanodyne Pharm 08/16/1957 Pain 11/19/2010 
Increased risk of 
abnormal heart 
rhythms (PR and 
QT prolongation) 
[28] 
Sibutramine Meridia Abbott 11/22/1997 Obesity 10/08/2010 
Increased risk of 
heart attack and 
stroke [29] 
Pergolide Permax Lilly 12/30/1988 Parkinson’s disease 03/29/2007 
Increased risk of 
heart valve disease  
[30] 










Valdecoxib Bextra Pfizer 11/16/2001 Pain 04/07/2005 





Table 2. Safety alerts concerning cardiovascular risk published between 2005 and 2010  
 
Drug Name Brand Name Company 
Approval 
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Saquinavir Invirase Roche 12/06/1995 HIV 10/21/2010 
Potential 
change in the 
electrical 
activity of the 















Prostate Cancer 10/20/2010 
Increased risk 
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WHY TESTING ENDOTHELIAL FUNCTION?  
 The endothelium is a large homeostatic organ that plays a major role in 
cardiovascular physiology and disease. Its structure might be seen as a simple cell 
monolayer lining the entire vascular lumens, but its functions are much more complex 
and relevant. Through the synthesis and release of several bioactive substances, primarily 
but not only nitric oxide (NO), it regulates vascular tone, and prevents vessels wall 
inflammation, smooth muscle cell proliferation, and thrombosis [46-48]. Several 
pathological circumstances may induce functional and structural alterations. The resultant 
endothelial dysfunction involves a systemic disorder that comprises the production of 
vasoconstricting and prothrombotic factors, the expression of adhesion molecules, and 
the impairment of the normal repair mechanisms. At present, we have available a wide 
range of invasive and non-invasive methods to assess this endothelial activation in vivo 
and in vitro [48, 49]. 
 
Clinical relevance of endothelial dysfunction and utility of endothelial function tests 
 All cardiovascular risk factors, such as diabetes mellitus, hypercholesterolemia, 
hypertension, obstructive sleep apnea and smoking [50-54], have shown to impair 
endothelial function. Although contradictory data exist [55], it has also been pointed out 
that endothelial dysfunction might be not only the consequence, but even a pathogenetic 
mechanism for the onset of some of them [55-59].  
 Endothelial dysfunction is recognized as one of the factors responsible for 
initiation and progression of atherosclerosis [60, 61], both for the loss of its protective 
properties and for the induction of an atherothrombotic substrate [62]. It is an 
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independent predictor for future major cardiovascular events [63], as it also contributes to 
destabilize the plaque, by changing its biology and composition [64], making it more 
prone to rupture and thus to acute cardiovascular events [65]. Besides, heart failure is a 
casual factor for endothelial dysfunction [66] and, at the same time, it is linked to worse 
outcomes and high mortality in patients with heart failure [67, 68]. 
 Currently, endothelial tests are being used for several applications. They are 
excellent approaches for a better understanding of the mechanisms involved in the 
genesis and progression of many different diseases (i.e. atherosclerosis [69], erectile 
dysfunction [70], pulmonary hypertension [71], renal insufficiency [72], migraine [73]); 
they are quite helpful in assessing the changes in endothelial function and clinical 
markers resulting from exercise [74], dietary [75-77], medical [78-80], percutaneous [81] 
or surgical interventions [82]; and one of their most promising advantages is their 
applicability as clinical diagnostic tool for identifying -at earlier stages- those patients 
with a high risk of cardiovascular events, in order to initiate or intensify the proper 
treatments [83, 84]. 
 
Drugs and endothelium 
 It has been observed in animals that endothelial function and structure may result 
damaged by three different drug-related mechanisms [85]: a) direct endothelial cell 
toxicity, through interactions with molecules expressed on the cell membranes; b) an 
increase in blood flow-induced shear stress, generated from prolonged vasodilatation or a 
marked increment in regional blood flow; c) an immune-mediated injury. Following any 
of them, there is a common endothelial activation –quite similar to the observed with the 
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major cardiovascular risks- that comprises synthesis and release of proinflammatory 
cytokines, upregulation of adhesion molecules, T cell and complement activation, and 
autoantibodies production. All these actions result in vessel wall inflammation, leading to 
an increase intimal permeability, membrane damage, intimal hyperplasia and cell death 
[86]. 
 The number of marketed drugs with proven arterial toxicity in animals is not 
negligible [85], and it would be possible that the list of drugs that induce endothelial 
dysfunction in humans was longer in case we tested all compounds. We will just mention 
below some of the most noticeable interactions, due to both their recent description and 
clinical relevance.  
 One of the particularly controversial topics in recent years [9, 11, 12] have been 
the market withdrawal of some cyclooxygenase 2 (COX-2) selective NSAIDs, and the 
FDA safety alert for the rest of COX-2 selective and non-selective NSAIDs due to 
potential serious adverse cardiovascular events [32, 44, 87]. While the exact mechanism 
by which these drugs increase cardiovascular risk is still not fully understood, today we 
have more clues about the pathological role of endothelial dysfunction on it [79, 88, 89]. 
COX-2 was thought to be only an inducible enzyme associated with inflammation and 
pain; but it is easily inducible in endothelial cells by shear stress too [90]. There, COX-2 
produces prostacyclin (PGI2), which promotes vasorelaxation and inhibits platelets 
activation. One of the postulated mechanisms is that the inhibition of COX-2 will induce 
the loss of these endothelial PGI2 cardioprotective effects, leading to the undesirable 
cardiovascular effects [91].  
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 In the last two decades, oncology is becoming a medical specialty with a highly 
productive research in new drugs. It is reducing the mortality and morbidity of patients 
with cancer, but at the same time is revealing a large number of cardiovascular ADRs. 
This fact may limit the use of some of these compounds, given that many of the signaling 
cascades inhibited in cancerous cells are also necessary for myocardial and vascular cells 
survival [92]. The vascular endothelial growth factor (VEGF) is essential for growth and 
survival of endothelial cells [93], so anti-VEGF drugs (i.e. bevacizumab, lapatinib, 
sunitinib, sorafenib) are a good paradigm [94].     
 The idea of raising protective high-density lipoprotein (HDL) seems attractive, as 
it is known to enhance endothelial function [95]. Therefore the early termination of a 
phase III clinical trial with torcetrapib [27], a cholesteryl ester transfer protein inhibitor, 
because of an increased risk of death and cardiac events, was not expected. The real 
cause of these adverse events is still unclear, but a low increase in the blood pressure and 
serum aldosterone are unlike to entirely explain the magnitude of the outcomes [96, 97]. 
The first evidences for torcetrapib-induced endothelial dysfunction in vivo are already 
published [98]. 
 In chronic kidney disease, oxidative stress and inflammation are associated 
with impaired activity of the nuclear 1 factor (erythroid-derived 2)-related factor 2 
(Nrf2) transcription factor. Bardoxolone methyl is a potent activator of the Nrf2 
pathway and was shown to reduce the serum creatinine concentration. However, 
significantly increased risks of heart failure and of the composite cardiovascular 
outcome (nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart 
failure, or death from cardiovascular causes) prompted termination of a 
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randomized trial in patients with type 2 diabetes and stage 4 chronic kidney disease 
[99]. It has been seen that through modulation of the endothelin pathway –a potent 
vasoconstrictor peptide produced in endothelial cells-, bardoxolone methyl may 
promote acute sodium and volume retention and increase blood pressure in patients 
with more advanced chronic kidney disease [100]. 
 Moreover, different antipsycotics (haloperidol, risperidone, chlorpromazine 
and clozapine) have been recently related to cytoxic effects and apoptosis of 
endothelial cells [101]. This might be one of the reasons for the significantly 
increased risk for stroke and coronary artery disease observed with the use of 
second-generation antipsycotics [102]. 
  
Endothelial function tests to be integrated in drugs development 
 It is beyond the scope of our article to provide a description of the tests that are 
used or that might be applied in the preclinical phases of drugs development. Besides, 
there are significant concerns regarding the uncertain extrapolation of some induced 
vascular toxic effects observed in animals to humans [85, 86]. Thus, we will just focus on 
detailing the evidence that might support, according to our opinion, the introduction of 
the best validated and less invasive techniques for the assessment of endothelial function 
in the clinical phases of drug development. 
 These techniques may be grouped into two categories: those tests that measure the 
appropriate endothelial respond to increased shear stress (flow-mediated dilatation 
[FMD] and reactive hyperemia peripheral arterial tonometry [RH-PAT]), and those that 
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evaluate the production of biomarkers of endothelial damage and repair (asymmetric 
dimethylarginine [ADMA] and endothelial progenitor cells [EPCs]).  
 The most widely used non-invasive test is the FMD, which consists in the 
ultrasound measurement of the changes in brachial artery diameter due to the release of 
endothelial NO, in respond to the increase in shear stress induced by the inflation and 
subsequent release of a sphygmomanometer cuff on the distal forearm. This response is 
depressed in subjects with atherosclerosis and cardiovascular risk factors [49]. The 
assessment of peripheral endothelial function by FMD is close related with coronary 
artery endothelial function [103]. FMD is an independent predictor of cardiovascular 
events in subjects with [104, 105] and without [83] previous cardiovascular disease.  
 More recently, another non-invasive technique to assess the peripheral endothelial 
function has been developed. RH-PAT measures the changes in digital pulse volume 
during a similarly induced reactive hyperemia. In the same way, this digital 
vasodilatation function is related to multiple traditional cardiovascular risk factors [106] 
and to coronary microvascular endothelial dysfunction [107]. RH-PAT is also an 
independent predictor of cardiovascular adverse events [84]. 
 Increased plasma levels of ADMA -an endogenous competitive antagonist of NO 
synthase that impairs endothelial function- are detected in subjects with cardiovascular 
risk factors and diseases [108], and are related to coronary endothelial dysfunction [109] 
and decreased branchial FMD responses [110]. Elevated ADMA levels are an 
independent predictor of future major adverse cardiac events [111] and all-cause 
mortality [112]. 
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 Endothelial function is related to the number of EPCs as these EPCs are 
responsible for maintaining endothelial integrity after many of the injuries. An inverse 
correlation has been shown between cardiovascular risks factors and diseases and the 
number and function of EPCs [113]. As seen above with the previous three tests, low 
levels of EPCs are also independent predictors of CAD progression [114] and worse 
cardiovascular outcomes [115, 116]. 
 
CONCLUSIONS 
 In the present article, we have shown that cardiovascular safety remains a key 
problem in drug development. Despite the approaches currently used to detect the 
toxicity along this process, patients continue to suffer severe cardiovascular side effects 
once the drugs are already in the market. It has been clearly stated that endothelial 
dysfunction plays a main role in the incidence of future major cardiovascular events, and 
that endothelial function tests are valuable tools to determinate the endothelial 
morphologic and functional integrity. Our review support the inclusion of some of these 
endothelial function tests in the hard process of drug development, for avoiding the 
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